ReviewTuberculosis and respiratory diseases2018
Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy.
Review in Tuberculosis and respiratory diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Psychosocial interventions to improve tuberculosis preventive treatment uptake and psychosocial outcomes: a systematic review.NPJ primary care respiratory medicine · 2025Pooled it
- Efficacy and safety of different regimens in the treatment of patients with latent tuberculosis infection: a systematic review and network meta-analysis of randomized controlled trials.Archives of public health = Archives belges de sante publique · 2023Pooled it
- Cost-effectiveness of latent tuberculosis infection testing and preventive treatment among TB contacts in China: a Markov model.BMC health services research · 2026Article
- Exploring the ethics of tuberculosis human challenge models.Journal of medical ethics · 2026Article
- Protection against reinfection with Mycobacterium tuberculosis extends across heterologous Mtb lineages.Mucosal immunology · 2026Article
- Recent advances in tuberculosis treatment: Towards shorter, safer, and more effective therapies.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Review
- Understanding tuberculosis among people with tuberculosis through an educational film: a qualitative study.BMJ open · 2025Article
- Review
- Aqueous extract-mediated green synthesis of CuO nanoparticles: Potential anti-tuberculosis agents.Food science & nutrition · 2024Article
- Article
- Genotyping of Mycobacterium tuberculosis complex isolated from humans and animals in northeastern Iran.Scientific reports · 2023Article
- Management of Tuberculosis Infection: Current Situation, Recent Developments and Operational Challenges.Pathogens (Basel, Switzerland) · 2023Review
- Clinical-Epidemiological Characteristics and Outcomes of Latent Tuberculosis Treatment at a Tertiary Center in Central-West Brazil from 2017 to 2019.Tropical medicine and infectious disease · 2022Article
- Tuberculosis challenges: Resistance, co-infection, diagnosis, and treatment.European journal of microbiology & immunology · 2022Review
- Article
- Introduction of short course treatment for latent tuberculosis infection at a primary care facility for refugees in Winnipeg, Canada: A mixed methods evaluation.Frontiers in public health · 2022Article
- Targeting Non-ReplicatingInternational journal of molecular sciences · 2021Review
- The Impact of Borderline Quantiferon-TB Gold Plus Results for Latent Tuberculosis Screening under Routine Conditions in a Low-Endemicity Setting.Journal of clinical microbiology · 2021Article
- Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study.Journal of Korean medical science · 2021Article
- Disseminated Tuberculosis in a Psoriasis Patient under Adalimumab Treatment despite the Chemoprophylaxis of Latent Tuberculosis: A Case Report.Annals of dermatology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of the treatment for latent tuberculosis infection (LTBI) has been underscored in the intermediate tuberculosis (TB) burden countries like South Korea. LTBI treatment is recommended only for patients at risk for progression to active TB-those with frequent exposure to active TB cases, and those with clinical risk factors (e.g., immunocompromised patients). Recently revised National Institute for Health and Care Excellence (NICE) guideline recommended that close contacts of individuals with active pulmonary or laryngeal TB, aged between 18 and 65 years, should undergo LTBI treatment. Various regimens for LTBI treatment were recommended in NICE, World Health Organization (WHO), and Centers for Disease Control and Prevention guidelines, and superiority of one recommended regimen over another was not yet established. Traditional 6 to 9 months of isoniazid (6H or 9H) regimen has an advantage of the most abundant evidence for clinical efficacy-60%-90% of estimated protective effect. However, 6H or 9H regimen is related with hepatotoxicity and low compliance. Four months of rifampin regimen is characterized by less hepatotoxicity and better compliance than 9H, but has few evidence of clinical efficacy. Three months of isoniazid plus rifampin was proved equivalence with 6H or 9H regimen in terms of efficacy and safety, which was recommended in NICE and WHO guidelines. The clinical efficacy of isoniazid plus rifapentine once-weekly regimen for 3 months was demonstrated recently, which is not yet introduced into South Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.